↓ Direkt till sidans innehåll
↓ Direkt till sidans sekundära innehåll (sidomenyn)

Tyck till om SwePub Sök här!

Träfflista för sökning "WFRF:(Lundin E) ;pers:(Osterborg A)"

Search: WFRF:(Lundin E) > Osterborg A

Result 1-10 of 19

Sort/group result

Sort by: Hits per page:

Enumeration	Reference	Cover	Find
1.	Palma, M, et al. (author) Very Early Effects of Ibrutinib on Tumor and Immune Cells in Blood and Lymph Nodes in Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) Patients 2016 In: BLOOD. - 0006-4971. ; 128:22 Conference paper (other academic/artistic)
2.	Karlsson, C, et al. (author) Alemtuzumab as first-line therapy for B-cell chronic lymphocytic leukemia: long-term follow-up of clinical effects, infectious complications and risk of Richter transformation 2006 In: Leukemia. - : Springer Science and Business Media LLC. - 0887-6924 .- 1476-5551. ; 20:12, s. 2204-2007 Journal article (other academic/artistic)
3.	Hagberg, H, et al. (author) Phase II study of alemtuzumab (Campath-1H) in patients with advanced mycosis fungoides/Sezary syndrome. 2001 In: BLOOD. - 0006-4971. ; 98:11, s. 806A-806A Conference paper (other academic/artistic)
4.	Hale, G, et al. (author) Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration 2004 In: Blood. - : American Society of Hematology. - 0006-4971 .- 1528-0020. ; 104:4, s. 948-955 Journal article (peer-reviewed)abstract Alemtuzumab is a humanized anti-CD52 antibody licensed for refractory B-cell chronic lymphocytic leukemia (B-CLL), when given intravenously at 30 mg thrice weekly. However, the intravenous route is associated with infusion-related reactions and is inconvenient. We measured blood concentrations in 30 relapsed patients treated with intravenous alemtuzumab and in 20 patients from a previously untreated group who received similar doses subcutaneously. Highest trough samples in the intravenous group were less than 0.5 μg/mL to 18.3 μg/mL (mean 5.4 μg/mL). The cumulative dose required to reach 1.0 μg/mL was 13 mg to 316 mg (mean 90 mg). Higher blood concentrations correlated with the achievement of better clinical responses and minimal residual disease. The highest measured concentrations in the subcutaneous group were similar (0.6 μg/mL to 24.8 μg/mL, mean 5.4 μg/mL). However, the cumulative dose to reach 1.0 μg/mL was higher: 146 mg to 1106 mg (mean 551 mg). No antiglobulin responses were detected in 30 patients given intravenous alemtuzumab whereas 2 of 32 patients given subcutaneous alemtuzumab made substantial anti-idiotype responses. Thus, subcutaneous alemtuzumab achieved concentrations similar to those for intravenous alemtuzumab, although with slightly higher cumulative doses. Subcutaneous alemtuzumab is more convenient and better tolerated but may be associated with some patients forming anti–alemtuzumab antibodies, particularly those patients who were previously untreated.
5.	Hale, G, et al. (author) Blood levels of alemtuzumab during treatment of patients with chronic lymphocytic leukemia. Comparison of intravenous and subcutaneous routes of administration. 2002 In: BLOOD. - 0006-4971. ; 100:11, s. 207A-207A Conference paper (other academic/artistic)
6.	Karlsson, C, et al. (author) Phase II study of subcutaneous alemtuzumab without dose escalation in patients with advanced-stage, relapsed chronic lymphocytic leukaemia 2009 In: British journal of haematology. - : Wiley. - 1365-2141 .- 0007-1048. ; 144:1, s. 78-85 Journal article (peer-reviewed)
7.	Karlsson, C, et al. (author) Virus reactivations and serology patterns following first-line therapy with alemtuzumab or fludarabine-based combination therapy in patients with chronic lymphocytic leukemia 2011 In: Blood cancer journal. - : Springer Science and Business Media LLC. - 2044-5385. ; 1:6, s. e22- Journal article (peer-reviewed)
8.	Lundin, J, et al. (author) A Phase 2 Study of Alemtuzumab-Ofatumumab (A plus O) Combination in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL) - an Update 2015 In: BLOOD. - 0006-4971. ; 126:23 Conference paper (other academic/artistic)
9.	Lundin, J, et al. (author) CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's Lymphoma 1998 In: Journal of clinical oncology : official journal of the American Society of Clinical Oncology. - 0732-183X. ; 16:10, s. 3257-3263 Journal article (peer-reviewed)
10.	Lundin, J, et al. (author) CAMPATH-1H therapy of patients with previously untreated chronic lymphocytic leukemia (CLL). 2000 In: ANNALS OF ONCOLOGY. - 0923-7534. ; 11, s. 96-96 Conference paper (other academic/artistic)

Skapa referenser, mejla, bekava och länka

Permalink

Result 1-10 of 19

Refine your search

Type of publication: journal article (11); conference paper (8)

Type of content: other academic/artistic (10); peer-reviewed (9)

Author/Editor: Osterborg, A (19)Undo refine; Lundin, J (19); Mellstedt, H (13); Kimby, E (12); Karlsson, C. (6); Tullgren, O (3); show more...; Hagberg, H (3); Bjorkholm, M (3); Hillmen, P. (3); Waldmann, H. (2); Wiklund, T (2); Hansson, L (1); Rossmann, ED (1); Thomas, J. (1); Sander, B (1); Wang, Q. (1); Johansson, E (1); Petrescu, A (1); Linde, A (1); Merup, M (1); Eriksson, M (1); Ma, S. (1); Palma, M (1); Juliusson, G (1); Juliusson, Gunnar (1); Wigzell, H (1); Halapi, E (1); Porwit-MacDonald, A (1); Nilsson, B (1); Rawstron, AC (1); Willemze, R (1); Brytting, M. (1); Werner, B (1); Blomberg, E (1); Harmenberg, U. (1); Norberg, B. (1); Hast, R (1); Hoglund, P (1); Freden, S (1); Cavallin-Ståhl, Eva (1); Sylvan, SE (1); Smith, E (1); Dahl, H (1); Hühn, D (1); Rezvany, MR (1); Werner, A. (1); Porwit, A (1); Jaremko, G (1); Berglof, A (1); Meinke, S (1); show less...

University: Karolinska Institutet (19); Uppsala University (1); Linköping University (1); Lund University (1)

Language: English (19)

Research subject (UKÄ/SCB): Medical and Health Sciences (1)

Year

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

Copyright © LIBRIS - National Library Systems
LIBRIS.kb.se

pil uppåt

Close

Copy and save the link in order to return to this view